Literature DB >> 24820751

Fibroblast growth factor 23 and risk of all-cause mortality and cardiovascular events: a meta-analysis of prospective cohort studies.

Yunjun Xiao1, Xianru Luo2, Wei Huang2, Jinzhou Zhang2, Chaoqiong Peng2.   

Abstract

Entities:  

Keywords:  Cardiovascular disease; Cohort studies; Fibroblast growth factor 23; Meta-analysis

Mesh：

Substances：

Year:  2014        PMID： 24820751     DOI： 10.1016/j.ijcard.2014.04.138

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN： 0167-5273            Impact factor:   4.164


× No keyword cloud information.
  8 in total

1.  The significance of micro- and macrovascular biomarkers on cardiovascular outcome in chronic kidney disease: a prospective cohort study.

Authors:  O Cseprekál; J Egresits; Á Tabák; J Nemcsik; Z Járai; L Babos; E Fodor; K Farkas; G Godina; K I Kárpáthi; L Kerkovits; A Marton; Z Nemcsik-Bencze; Z Németh; L Sallai; I Kiss; A Tislér
Journal:  J Hum Hypertens       Date:  2015-10-01       Impact factor: 3.012

2.  PTH, FGF23, and Intensive Blood Pressure Lowering in Chronic Kidney Disease Participants in SPRINT.

Authors:  Charles Ginsberg; Timothy E Craven; Michel B Chonchol; Alfred K Cheung; Mark J Sarnak; Walter T Ambrosius; Anthony A Killeen; Kalani L Raphael; Udayan Y Bhatt; Jing Chen; Glenn M Chertow; Barry I Freedman; Suzanne Oparil; Vasilios Papademetriou; Barry M Wall; Clinton B Wright; Joachim H Ix; Michael G Shlipak
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-13       Impact factor: 8.237

3.  Fibroblast Growth Factor 23: A Biomarker of Kidney Function Decline.

Authors:  David A Drew; Ronit Katz; Stephen Kritchevsky; Joachim H Ix; Michael G Shlipak; Anne B Newman; Andy Hoofnagle; Linda Fried; Mark J Sarnak; Orlando M Gutierrez
Journal:  Am J Nephrol       Date:  2018-04-05       Impact factor: 3.754

4.  Elevated serum fibroblast growth factor 23 levels as an indicator of lower extremity atherosclerotic disease in Chinese patients with type 2 diabetes mellitus.

Authors:  Xingxing He; Xiang Hu; Xiaojing Ma; Hang Su; Lingwen Ying; Jiahui Peng; Xiaoping Pan; Yuqian Bao; Jian Zhou; Weiping Jia
Journal:  Cardiovasc Diabetol       Date:  2017-06-15       Impact factor: 9.951

Review 5.  Fibroblast growth factor 23: are we ready to use it in clinical practice?

Authors:  Annet Bouma-de Krijger; Marc G Vervloet
Journal:  J Nephrol       Date:  2020-03-04       Impact factor: 3.902

Review 6.  FGF23: A Review of Its Role in Mineral Metabolism and Renal and Cardiovascular Disease.

Authors:  Anna Kurpas; Karolina Supeł; Karolina Idzikowska; Marzenna Zielińska
Journal:  Dis Markers       Date:  2021-05-17       Impact factor: 3.434

7.  A Low-Sodium DASH Dietary Pattern Affects Serum Markers of Inflammation and Mineral Metabolism in Adults with Elevated Blood Pressure.

Authors:  Valerie K Sullivan; Lawrence J Appel; Jesse C Seegmiller; Scott T McClure; Casey M Rebholz
Journal:  J Nutr       Date:  2021-10-01       Impact factor: 4.687

8.  FGF23 and Cause-Specific Mortality in Community-Living Individuals-The Health, Aging, and Body Composition Study.

Authors:  Shilpa Sharma; Ronit Katz; Ruth F Dubin; David A Drew; Orlando M Gutierrez; Michael G Shlipak; Mark J Sarnak; Joachim H Ix
Journal:  J Am Geriatr Soc       Date:  2020-11-10       Impact factor: 7.538
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.